NASDAQ:NBRV - Nabriva Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$5.43 +0.25 (+4.83 %)
(As of 05/20/2018 02:11 PM ET)
Previous Close$5.43
Today's Range$5.16 - $5.47
52-Week Range$4.39 - $14.10
Volume354,614 shs
Average Volume283,163 shs
Market Capitalization$199.37 million
P/E RatioN/A
Dividend YieldN/A
Beta1.78

About Nabriva Therapeutics (NASDAQ:NBRV)

Nabriva Therapeutics logoNabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection. The company is also developing BC-7013, a semi-synthetic compound derived from pleuromutilin, which has completed a Phase 1 clinical trial for the treatment of Gram-positive infections, including uncomplicated skin and skin structure infections. In addition, it is developing lefamulin for use in the treatment of ventilator-associated bacterial pneumonia or hospital-acquired bacterial pneumonia and sexually transmitted infections. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

Receive NBRV News and Ratings via Email

Sign-up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NBRV
CUSIPN/A
Phone610-816-6640

Debt

Debt-to-Equity RatioN/A
Current Ratio8.66
Quick Ratio8.66

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$5.32 million
Price / Sales37.48
Cash FlowN/A
Price / CashN/A
Book Value$2.41 per share
Price / Book2.25

Profitability

EPS (Most Recent Fiscal Year)($2.49)
Net Income$-74,350,000.00
Net Margins-600.34%
Return on Equity-79.30%
Return on Assets-66.97%

Miscellaneous

Employees88
Outstanding Shares36,720,000

Nabriva Therapeutics (NASDAQ:NBRV) Frequently Asked Questions

What is Nabriva Therapeutics' stock symbol?

Nabriva Therapeutics trades on the NASDAQ under the ticker symbol "NBRV."

How were Nabriva Therapeutics' earnings last quarter?

Nabriva Therapeutics (NASDAQ:NBRV) posted its quarterly earnings results on Tuesday, May, 8th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.59) by $0.23. The biotechnology company had revenue of $7.55 million for the quarter, compared to analyst estimates of $1.27 million. Nabriva Therapeutics had a negative net margin of 600.34% and a negative return on equity of 79.30%. View Nabriva Therapeutics' Earnings History.

When is Nabriva Therapeutics' next earnings date?

Nabriva Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Nabriva Therapeutics.

What price target have analysts set for NBRV?

8 brokers have issued 12 month price objectives for Nabriva Therapeutics' stock. Their predictions range from $10.00 to $24.00. On average, they anticipate Nabriva Therapeutics' share price to reach $17.6250 in the next twelve months. View Analyst Ratings for Nabriva Therapeutics.

What are Wall Street analysts saying about Nabriva Therapeutics stock?

Here are some recent quotes from research analysts about Nabriva Therapeutics stock:
  • 1. Needham & Company LLC analysts commented, "Nabriva reported 1Q18 financial results today and we spoke w/ mgmt for an update. Mgmt reiterated guidance for top-line results from the second of two Phase 3 trials of lead antibiotic lefamulin in Community Pneumonia (CABP) in 2Q18. We continue to expect a positive outcome and reiterate BUY rating. We believe the opportunity for lefamulin in Community Pneumonia is misunderstood and underappreciated by investors. We acknowledge challenges for antibiotics within the hospital, but believe oral lefamulin can be relevant in the large outpatient community setting." (5/8/2018)
  • 2. According to Zacks Investment Research, "Nabriva Therapeutics is a biopharmaceutical company engaged in the research and development of new medicines to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics' medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations. Nabriva Therapeutics' lead product candidate, lefamulin, is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. The company believes that lefamulin is the first antibiotic with a novel mechanism of action to have reached late-stage clinical development in more than a decade. Nabriva has announced positive topline data for lefamulin from the first of its two global, registrational Phase 3 clinical trials evaluating lefamulin in patients with moderate to severe community-acquired bacterial pneumonia (CABP). " (4/4/2018)
  • 3. HC Wainwright analysts commented, "Updated Results from SITC Confirm IMO-2125 Clinical Benefit; Reiterate Buy IMO-2125 activates innate immune response against tumor. Last week we attended the annual meeting for Society for Immunotherapy of Cancer (SITC) held in National Harbor, Maryland. At the conference, Dr. Haymaker from MD Anderson Cancer Center presented additional results from the ongoing Phase 1/2 clinical study of IMO-2125, a TLR9 agonist from Idera. Recall, IMO-2125 is being investigated as a combinational therapy together with Bristol-Myers Squibb’s (BMY; not rated) Yervoy (ipilimumab) for the treatment of PD-1 refractory melanoma. Previously, it was reported that the combination of IMO-2125 and ipilimumab achieved an overall response rate (ORR) of 44%. The updated results presented at the SITC conference included an additional patient with confirmed response, which improved the ORR from the study to 50% (5 out of 10 patients). Importantly, gene expression analysis in patients’ tumor biopsies, taken 24 hours after IMO-2125 injections, suggests that IMO-2125 upregulates interferon-alpha production, promotes dendritic cells maturation and the inflow of macrophages at the tumor site. Moreover, considering that ipilimumab has not yet been administered at the time of the biopsy, the observed activation of immune system can be fully attributed to IMO-2125, rather than the drug combination. In our view, these results provide additional confidence in the clinical activity of IMO-2125 and potential success of the planned Phase 3 study, which is expected to start in 1Q18." (11/16/2017)
  • 4. Cantor Fitzgerald analysts commented, "Yesterday, after market close, Nabriva announced that Elyse Seltzer, M.D., is resigning as CMO effective 9/30/2017." (9/1/2017)

Who are some of Nabriva Therapeutics' key competitors?

Who are Nabriva Therapeutics' key executives?

Nabriva Therapeutics' management team includes the folowing people:
  • Dr. Colin Broom, CEO, Interim Chief Medical Officer & Director (Age 62)
  • Mr. Gary L. Sender, Chief Financial Officer (Age 56)
  • Mr. Steven P. Gelone Pharm. D, Chief Scientific Officer (Age 50)
  • Mr. Thomas Lembck, Chief Information Officer
  • Mr. David Garrett, Head of Investor Relations, VP & Corp. Controller

Has Nabriva Therapeutics been receiving favorable news coverage?

Media headlines about NBRV stock have trended somewhat positive recently, according to Accern. The research firm identifies positive and negative press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Nabriva Therapeutics earned a media sentiment score of 0.14 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 47.05 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are Nabriva Therapeutics' major shareholders?

Nabriva Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Millennium Management LLC (2.24%), Acuta Capital Partners LLC (1.52%), BlackRock Inc. (1.23%), Prosight Management LP (0.66%), Dimensional Fund Advisors LP (0.30%) and Trexquant Investment LP (0.13%). Company insiders that own Nabriva Therapeutics stock include Colin Md Broom, Francesco Maria Lavino, Gary Sender, George Harrison Talbot, Hbm Healthcare Investments (Ca and Vivo Capital Viii, Llc. View Institutional Ownership Trends for Nabriva Therapeutics.

Which major investors are selling Nabriva Therapeutics stock?

NBRV stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Prosight Management LP, Millennium Management LLC and Acuta Capital Partners LLC. Company insiders that have sold Nabriva Therapeutics company stock in the last year include George Harrison Talbot and Hbm Healthcare Investments (Ca. View Insider Buying and Selling for Nabriva Therapeutics.

Which major investors are buying Nabriva Therapeutics stock?

NBRV stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Dimensional Fund Advisors LP, Trexquant Investment LP, DRW Securities LLC and JPMorgan Chase & Co.. Company insiders that have bought Nabriva Therapeutics stock in the last two years include Colin Md Broom, Francesco Maria Lavino, Gary Sender and Vivo Capital Viii, Llc. View Insider Buying and Selling for Nabriva Therapeutics.

How do I buy shares of Nabriva Therapeutics?

Shares of NBRV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nabriva Therapeutics' stock price today?

One share of NBRV stock can currently be purchased for approximately $5.43.

How big of a company is Nabriva Therapeutics?

Nabriva Therapeutics has a market capitalization of $199.37 million and generates $5.32 million in revenue each year. The biotechnology company earns $-74,350,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. Nabriva Therapeutics employs 88 workers across the globe.

How can I contact Nabriva Therapeutics?

Nabriva Therapeutics' mailing address is 56 FITZWILLIAM SQUARE, DUBLIN L2, 19406. The biotechnology company can be reached via phone at 610-816-6640 or via email at [email protected]


MarketBeat Community Rating for Nabriva Therapeutics (NBRV)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  186 (Vote Outperform)
Underperform Votes:  119 (Vote Underperform)
Total Votes:  305
MarketBeat's community ratings are surveys of what our community members think about Nabriva Therapeutics and other stocks. Vote "Outperform" if you believe NBRV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBRV will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Nabriva Therapeutics (NASDAQ:NBRV) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
8 Wall Street analysts have issued ratings and price targets for Nabriva Therapeutics in the last 12 months. Their average twelve-month price target is $17.6250, suggesting that the stock has a possible upside of 224.59%. The high price target for NBRV is $24.00 and the low price target for NBRV is $10.00. There are currently 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $17.6250$17.6250$18.7143$20.4286
Price Target Upside: 224.59% upside226.99% upside211.90% upside268.75% upside

Nabriva Therapeutics (NASDAQ:NBRV) Consensus Price Target History

Price Target History for Nabriva Therapeutics (NASDAQ:NBRV)

Nabriva Therapeutics (NASDAQ:NBRV) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/8/2018Needham & Company LLCReiterated RatingBuy$18.00MediumView Rating Details
5/8/2018Cantor FitzgeraldSet Price TargetBuy$16.00MediumView Rating Details
3/21/2018Bank of AmericaInitiated CoverageBuy ➝ Buy$10.00HighView Rating Details
3/19/2018WedbushReiterated RatingOutperformHighView Rating Details
1/17/2018Morgan StanleyInitiated CoverageOverweight ➝ Overweight$10.00HighView Rating Details
11/16/2017HC WainwrightReiterated RatingBuy$20.00N/AView Rating Details
9/18/2017Leerink SwannReiterated RatingOutperform$20.00 ➝ $22.00MediumView Rating Details
9/18/2017SunTrust BanksBoost Price TargetBuy$20.00 ➝ $24.00HighView Rating Details
12/20/2016Royal Bank of CanadaSet Price TargetBuy$22.00N/AView Rating Details
(Data available from 5/20/2016 forward)

Earnings

Nabriva Therapeutics (NASDAQ:NBRV) Earnings History and Estimates Chart

Earnings by Quarter for Nabriva Therapeutics (NASDAQ:NBRV)

Nabriva Therapeutics (NASDAQ:NBRV) Earnings Estimates

2018 EPS Consensus Estimate: ($2.32)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.75)($0.63)($0.69)
Q2 20182($0.63)($0.46)($0.55)
Q3 20182($0.67)($0.32)($0.50)
Q4 20182($0.77)($0.41)($0.59)

Nabriva Therapeutics (NASDAQ NBRV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018        
5/8/20183/31/2018($0.59)($0.36)$1.27 million$7.55 millionViewN/AView Earnings Details
3/16/2018Q4 2017($0.54)($0.60)$1.37 million$1.12 millionViewN/AView Earnings Details
11/9/2017Q3 2017($0.59)($0.66)$1.32 million$0.97 millionViewN/AView Earnings Details
8/7/20176/30/2017($5.83)($0.54)$1.34 million$1.05 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.57)($0.56)$1.54 million$1.68 millionViewN/AView Earnings Details
3/24/2017Q4 2016($0.70)($0.69)$1.42 million$2.31 millionViewN/AView Earnings Details
11/16/2016Q3($0.55)($0.66)$1.60 millionViewN/AView Earnings Details
8/9/2016Q2 2016($0.71)($0.56)ViewN/AView Earnings Details
5/10/2016Q1 2016($0.50)($0.64)$1.08 million$1.42 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Nabriva Therapeutics (NASDAQ:NBRV) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Nabriva Therapeutics (NASDAQ NBRV) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.75%
Institutional Ownership Percentage: 61.39%
Insider Trading History for Nabriva Therapeutics (NASDAQ:NBRV)
Institutional Ownership by Quarter for Nabriva Therapeutics (NASDAQ:NBRV)

Nabriva Therapeutics (NASDAQ NBRV) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/29/2017Francesco Maria LavinoInsiderBuy1,569$6.29$9,869.01View SEC Filing  
9/22/2017Colin Md BroomCEOBuy2,588$8.35$21,609.8087,151View SEC Filing  
9/22/2017Gary SenderCFOBuy2,000$8.21$16,420.004,200View SEC Filing  
9/18/2017Vivo Capital Viii, LlcMajor ShareholderBuy52,631$9.46$497,889.26View SEC Filing  
9/14/2017Hbm Healthcare Investments (CaMajor ShareholderSell36,608$8.56$313,364.48View SEC Filing  
8/31/2017Hbm Healthcare Investments (CaMajor ShareholderSell639$9.50$6,070.502,370,735View SEC Filing  
8/8/2017Hbm Healthcare Investments (CaMajor ShareholderSell19,803$10.50$207,931.502,373,387View SEC Filing  
8/7/2017Hbm Healthcare Investments (CaMajor ShareholderSell17,790$10.50$186,795.002,373,387View SEC Filing  
7/28/2017Hbm Healthcare Investments (CaMajor ShareholderSell6,585$10.51$69,208.352,391,177View SEC Filing  
7/24/2017Hbm Healthcare Investments (CaMajor ShareholderSell160$10.50$1,680.002,397,762View SEC Filing  
7/20/2017Hbm Healthcare Investments (CaMajor ShareholderSell44,231$10.50$464,425.502,421,367View SEC Filing  
7/18/2017Hbm Healthcare Investments (CaMajor ShareholderSell69,854$10.51$734,165.542,490,952View SEC Filing  
7/13/2017Hbm Healthcare Investments (CaMajor ShareholderSell57,175$10.53$602,052.752,565,661View SEC Filing  
7/7/2017Hbm Healthcare Investments (CaMajor ShareholderSell2,695$10.52$28,351.402,569,315View SEC Filing  
7/3/2017Hbm Healthcare Investments (CaMajor ShareholderSell13,127$10.94$143,609.382,583,229View SEC Filing  
6/30/2017Hbm Healthcare Investments (CaMajor ShareholderSell1,775$10.94$19,418.502,583,229View SEC Filing  
6/29/2017Hbm Healthcare Investments (CaMajor ShareholderSell8,558$10.96$93,795.682,591,396View SEC Filing  
6/19/2017George Harrison TalbotDirectorSell170$93.18$15,840.603,249View SEC Filing  
5/30/2017George Harrison TalbotDirectorSell210$101.26$21,264.603,449View SEC Filing  
5/25/2017George Harrison TalbotDirectorSell325$100.56$32,682.003,854View SEC Filing  
5/16/2017George Harrison TalbotDirectorSell200$102.44$20,488.003,351View SEC Filing  
5/15/2017George Harrison TalbotDirectorSell50$101.50$5,075.003,351View SEC Filing  
4/28/2017Hbm Healthcare Investments (CaMajor ShareholderSell15,939$11.02$175,647.782,609,192View SEC Filing  
4/21/2017Hbm Healthcare Investments (CaMajor ShareholderSell2,622$11.04$28,946.882,609,901View SEC Filing  
4/20/2017Hbm Healthcare Investments (CaMajor ShareholderSell23,932$11.11$265,884.522,624,633View SEC Filing  
4/13/2017Hbm Healthcare Investments (CaMajor ShareholderSell32,831$11.24$369,020.442,660,689View SEC Filing  
4/10/2017Hbm Healthcare Investments (CaMajor ShareholderSell90,594$10.96$992,910.24269,371View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Nabriva Therapeutics (NASDAQ NBRV) News Headlines

Source:
DateHeadline
Zacks: Analysts Expect Nabriva Therapeutics (NBRV) Will Announce Quarterly Sales of $1.60 MillionZacks: Analysts Expect Nabriva Therapeutics (NBRV) Will Announce Quarterly Sales of $1.60 Million
www.americanbankingnews.com - May 17 at 4:10 AM
Nabriva Therapeutics (NBRV) Rating Lowered to Sell at ValuEngineNabriva Therapeutics (NBRV) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - May 16 at 4:51 PM
Nabriva Therapeutics (NBRV) Expected to Post Earnings of -$0.56 Per ShareNabriva Therapeutics (NBRV) Expected to Post Earnings of -$0.56 Per Share
www.americanbankingnews.com - May 15 at 9:12 AM
Is the Options Market Predicting a Spike in Nabriva Therapeutics (NBRV) Stock?Is the Options Market Predicting a Spike in Nabriva Therapeutics (NBRV) Stock?
finance.yahoo.com - May 11 at 10:14 AM
Nabriva Therapeutics AG (NBRV) PT Lowered to $22 at SunTrust; Nabriva on Track to Release LEAP2 Phase III Data ...Nabriva Therapeutics AG (NBRV) PT Lowered to $22 at SunTrust; Nabriva on Track to Release LEAP2 Phase III Data ...
www.streetinsider.com - May 10 at 9:28 AM
BRIEF-Nabriva Therapeutics Reports Q1 Loss Per Share $0.36BRIEF-Nabriva Therapeutics Reports Q1 Loss Per Share $0.36
www.reuters.com - May 10 at 9:28 AM
Nabriva Therapeutics (NBRV) Posts Quarterly  Earnings Results, Beats Estimates By $0.23 EPSNabriva Therapeutics (NBRV) Posts Quarterly Earnings Results, Beats Estimates By $0.23 EPS
www.americanbankingnews.com - May 9 at 7:56 PM
Needham & Company LLC Reiterates Buy Rating for Nabriva Therapeutics (NBRV)Needham & Company LLC Reiterates Buy Rating for Nabriva Therapeutics (NBRV)
www.americanbankingnews.com - May 8 at 9:15 PM
Nabriva Therapeutics (NBRV) Given a $16.00 Price Target by Cantor Fitzgerald AnalystsNabriva Therapeutics (NBRV) Given a $16.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - May 8 at 6:26 PM
Nabriva Therapeutics beats by $0.03Nabriva Therapeutics beats by $0.03
seekingalpha.com - May 8 at 9:14 AM
Nabriva Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate HighlightsNabriva Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights
finance.yahoo.com - May 8 at 9:14 AM
Flavor Of The Month: OvaScience And MoreFlavor Of The Month: OvaScience And More
finance.yahoo.com - May 7 at 4:46 PM
Nabriva Therapeutics (NBRV) Given Consensus Rating of "Buy" by AnalystsNabriva Therapeutics (NBRV) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - May 3 at 5:49 AM
Nabriva Therapeutics (NBRV) Raised to "Hold" at ValuEngineNabriva Therapeutics (NBRV) Raised to "Hold" at ValuEngine
www.americanbankingnews.com - May 2 at 11:37 PM
 Brokerages Expect Nabriva Therapeutics (NBRV) Will Announce Quarterly Sales of $1.27 Million Brokerages Expect Nabriva Therapeutics (NBRV) Will Announce Quarterly Sales of $1.27 Million
www.americanbankingnews.com - April 29 at 2:14 AM
 Brokerages Anticipate Nabriva Therapeutics (NBRV) to Post -$0.59 EPS Brokerages Anticipate Nabriva Therapeutics (NBRV) to Post -$0.59 EPS
www.americanbankingnews.com - April 27 at 9:10 PM
Nabriva Therapeutics to Participate in Two Investor Conferences in MayNabriva Therapeutics to Participate in Two Investor Conferences in May
finance.yahoo.com - April 25 at 9:41 AM
Nabriva Therapeutics (NBRV) Receives "Overweight" Rating from Cantor FitzgeraldNabriva Therapeutics (NBRV) Receives "Overweight" Rating from Cantor Fitzgerald
www.americanbankingnews.com - April 20 at 3:39 PM
Cantor Fitzgerald Analysts Give Nabriva Therapeutics (NBRV) a $16.00 Price TargetCantor Fitzgerald Analysts Give Nabriva Therapeutics (NBRV) a $16.00 Price Target
www.americanbankingnews.com - April 19 at 12:16 PM
Zacks Investment Research Upgrades Nabriva Therapeutics (NBRV) to "Hold"Zacks Investment Research Upgrades Nabriva Therapeutics (NBRV) to "Hold"
www.americanbankingnews.com - April 17 at 9:15 PM
Nabriva (NBRV) to Present Data Showing Potential of Lefamulin for Patients with Community-acquired Bacterial PneumoniaNabriva (NBRV) to Present Data Showing Potential of Lefamulin for Patients with Community-acquired Bacterial Pneumonia
www.streetinsider.com - April 14 at 9:20 AM
Nabriva Therapeutics plc - (NBRV) Expected to Announce Quarterly Sales of $1.27 MillionNabriva Therapeutics plc - (NBRV) Expected to Announce Quarterly Sales of $1.27 Million
www.americanbankingnews.com - April 12 at 1:47 AM
Nabriva Therapeutics (NBRV) Upgraded at Zacks Investment ResearchNabriva Therapeutics (NBRV) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 11 at 6:13 PM
-$0.59 EPS Expected for Nabriva Therapeutics plc - (NBRV) This Quarter-$0.59 EPS Expected for Nabriva Therapeutics plc - (NBRV) This Quarter
www.americanbankingnews.com - April 10 at 11:16 PM
Nabriva Therapeutics (NBRV) Downgraded by Zacks Investment Research to HoldNabriva Therapeutics (NBRV) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - April 10 at 12:01 PM
Nabriva Therapeutics plc - (NBRV) Receives Consensus Rating of "Buy" from AnalystsNabriva Therapeutics plc - (NBRV) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - April 8 at 5:19 AM
Nabriva Therapeutics (NBRV) Upgraded to "Hold" by Zacks Investment ResearchNabriva Therapeutics (NBRV) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - April 4 at 1:03 PM
Nabriva Therapeutics (NBRV) Upgraded to "Sell" at ValuEngineNabriva Therapeutics (NBRV) Upgraded to "Sell" at ValuEngine
www.americanbankingnews.com - April 3 at 11:38 AM
Blog Exposure - Nabriva Therapeutics Collaborated with Roivant to Commercialize Lefamulin in Greater ChinaBlog Exposure - Nabriva Therapeutics Collaborated with Roivant to Commercialize Lefamulin in Greater China
finance.yahoo.com - March 29 at 9:33 AM
Nabriva Therapeutics (NBRV) Earns Overweight Rating from Analysts at Morgan StanleyNabriva Therapeutics (NBRV) Earns Overweight Rating from Analysts at Morgan Stanley
www.americanbankingnews.com - March 27 at 6:16 PM
Nabriva and Roivant team up to commercialize lefamulin in ChinaNabriva and Roivant team up to commercialize lefamulin in China
seekingalpha.com - March 27 at 9:11 AM
Nabriva Therapeutics and Roivant Sciences Enter into License Agreement to Develop and Commercialize Lefamulin in Greater ChinaNabriva Therapeutics and Roivant Sciences Enter into License Agreement to Develop and Commercialize Lefamulin in Greater China
finance.yahoo.com - March 27 at 9:11 AM
$1.27 Million in Sales Expected for Nabriva Therapeutics plc - (NBRV) This Quarter$1.27 Million in Sales Expected for Nabriva Therapeutics plc - (NBRV) This Quarter
www.americanbankingnews.com - March 26 at 1:50 AM
 Analysts Anticipate Nabriva Therapeutics plc - (NBRV) Will Post Earnings of -$0.63 Per Share Analysts Anticipate Nabriva Therapeutics plc - (NBRV) Will Post Earnings of -$0.63 Per Share
www.americanbankingnews.com - March 24 at 11:16 PM
Nabriva Therapeutics plc - Forecasted to Earn FY2018 Earnings of ($2.03) Per Share (NBRV)Nabriva Therapeutics plc - Forecasted to Earn FY2018 Earnings of ($2.03) Per Share (NBRV)
www.americanbankingnews.com - March 23 at 10:38 AM
Wedbush Weighs in on Nabriva Therapeutics plc -s Q1 2018 Earnings (NBRV)Wedbush Weighs in on Nabriva Therapeutics plc -'s Q1 2018 Earnings (NBRV)
www.americanbankingnews.com - March 22 at 8:32 AM
Nabriva Therapeutics (NBRV) Now Covered by Analysts at Bank of AmericaNabriva Therapeutics (NBRV) Now Covered by Analysts at Bank of America
www.americanbankingnews.com - March 21 at 7:48 PM
Nabriva (NBRV) Names Jennifer Schranz, MD, as Chief Medical Officer - StreetInsider.comNabriva (NBRV) Names Jennifer Schranz, MD, as Chief Medical Officer - StreetInsider.com
www.streetinsider.com - March 21 at 4:58 PM
Nabriva Therapeutics Appoints Jennifer Schranz, MD, as Chief Medical Officer - GlobeNewswire (press release)Nabriva Therapeutics Appoints Jennifer Schranz, MD, as Chief Medical Officer - GlobeNewswire (press release)
globenewswire.com - March 21 at 4:58 PM
Nabriva Therapeutics plc - Forecasted to Post FY2022 Earnings of ($0.01) Per Share (NBRV)Nabriva Therapeutics plc - Forecasted to Post FY2022 Earnings of ($0.01) Per Share (NBRV)
www.americanbankingnews.com - March 21 at 4:40 PM
Nabriva Therapeutics (NBRV) Earns Outperform Rating from WedbushNabriva Therapeutics (NBRV) Earns Outperform Rating from Wedbush
www.americanbankingnews.com - March 21 at 11:56 AM
Nabriva Therapeutics (NBRV) Rating Lowered to Sell at Zacks Investment ResearchNabriva Therapeutics (NBRV) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - March 21 at 10:14 AM
Nabriva Therapeutics Appoints Jennifer Schranz, M.D., as Chief Medical OfficerNabriva Therapeutics Appoints Jennifer Schranz, M.D., as Chief Medical Officer
finance.yahoo.com - March 21 at 9:46 AM
Nabriva Therapeutics Reports 2017 Financial Results and Recent Corporate Highlights - GlobeNewswire (press release)Nabriva Therapeutics Reports 2017 Financial Results and Recent Corporate Highlights - GlobeNewswire (press release)
globenewswire.com - March 16 at 10:04 AM
Nabriva Therapeutics Reports 2017 Financial Results and Recent Corporate HighlightsNabriva Therapeutics Reports 2017 Financial Results and Recent Corporate Highlights
finance.yahoo.com - March 16 at 10:04 AM
Nabriva Therapeutics to Present at the Needham and Company 17th Annual Healthcare ConferenceNabriva Therapeutics to Present at the Needham and Company 17th Annual Healthcare Conference
finance.yahoo.com - March 14 at 12:17 PM
Nabriva Therapeutics plc - (NBRV) Receives Average Rating of "Buy" from AnalystsNabriva Therapeutics plc - (NBRV) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - March 14 at 5:52 AM
$1.37 Million in Sales Expected for Nabriva Therapeutics plc - (NBRV) This Quarter$1.37 Million in Sales Expected for Nabriva Therapeutics plc - (NBRV) This Quarter
www.americanbankingnews.com - March 9 at 3:32 AM
Prosight Management LP Acquires Shares of 491,395 Nabriva Therapeutics plc - (NBRV)Prosight Management LP Acquires Shares of 491,395 Nabriva Therapeutics plc - (NBRV)
www.americanbankingnews.com - March 5 at 2:55 PM
Nabriva Therapeutics plc - (NBRV) Expected to Announce Quarterly Sales of $1.48 MillionNabriva Therapeutics plc - (NBRV) Expected to Announce Quarterly Sales of $1.48 Million
www.americanbankingnews.com - February 21 at 12:36 PM

SEC Filings

Nabriva Therapeutics (NASDAQ:NBRV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Nabriva Therapeutics (NASDAQ:NBRV) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Nabriva Therapeutics (NASDAQ NBRV) Stock Chart for Sunday, May, 20, 2018

Loading chart…

This page was last updated on 5/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.